Baker Bros. Advisors LP 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Baker Bros. Advisors LP disclosed 84 US equity positions worth $20.0bn in its Q2 2026 13F filing. The largest position was INCY at 17.5% of the reported book, followed by ONC and RVMD. Against the Q1 2026 filing, it opened 1 new position, added to 9 and reduced 5 among the top 50 holdings.
What did Baker Bros. Advisors LP own in Q2 2026? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | INCY Incyte Corporation | Healthcare | 17.5% | $3.5bn | 30,762,330 | 0% | held |
| 2 | ONC BeOne Medicines Ltd. | Healthcare | 12.6% | $2.5bn | 8,801,567 | 0% | held |
| 3 | RVMD Revolution Medicines, Inc. | Healthcare | 10.7% | $2.1bn | 11,443,357 | 20% | added |
| 4 | MDGL Madrigal Pharmaceuticals, Inc. | Healthcare | 5.8% | $1.2bn | 2,143,131 | 0% | held |
| 5 | ACAD ACADIA Pharmaceuticals Inc. | Healthcare | 5.4% | $1.1bn | 42,912,904 | 0% | held |
| 6 | KYMR Kymera Therapeutics, Inc. | Healthcare | 5.0% | $992.7m | 8,657,242 | 0% | held |
| 7 | INSM Insmed Incorporated | Healthcare | 4.7% | $937.8m | 8,796,111 | 19% | added |
| 8 | CELC Celcuity Inc. | Healthcare | 4.2% | $828.2m | 7,915,792 | 0% | held |
| 9 | KOD Kodiak Sciences Inc. | Healthcare | 3.9% | $776.1m | 19,919,186 | 0% | held |
| 10 | RYTM Rhythm Pharmaceuticals, Inc. | Healthcare | 3.1% | $622.3m | 5,604,483 | 0% | held |
| 11 | PRAX Praxis Precision Medicines, Inc. | Healthcare | 2.9% | $587.0m | 1,753,198 | 0% | held |
| 12 | ALKS Alkermes plc | Healthcare | 2.6% | $524.6m | 10,012,267 | 0% | held |
| 13 | SMMT Summit Therapeutics Inc. | Healthcare | 2.4% | $477.7m | 32,786,348 | -10% | reduced |
| 14 | GRAL GRAIL, Inc. | Healthcare | 1.4% | $275.0m | 4,028,614 | 0% | held |
| 15 | ABCL AbCellera Biologics Inc. | Healthcare | 1.3% | $259.1m | 33,012,138 | 9% | added |
| 16 | IMVT Immunovant, Inc. | Healthcare | 1.0% | $209.4m | 5,435,220 | -0% | held |
| 17 | IDYA IDEAYA Biosciences, Inc. | Healthcare | 0.9% | $186.7m | 5,010,030 | 27% | added |
| 18 | Kiniksa Pharmaceuticals International, plc | 0.9% | $181.3m | 2,834,643 | 0% | held | |
| 19 | ROIV Roivant Sciences Ltd. | Healthcare | 0.8% | $166.9m | 4,716,831 | -3% | reduced |
| 20 | ARWR Arrowhead Pharmaceuticals, Inc. | Healthcare | 0.8% | $162.4m | 1,992,783 | 0% | held |
| 21 | IONS Ionis Pharmaceuticals, Inc. | Healthcare | 0.8% | $162.4m | 2,047,727 | 0% | held |
| 22 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 0.8% | $150.4m | 3,701,719 | -44% | reduced |
| 23 | REPL Replimune Group, Inc. | Healthcare | 0.6% | $122.3m | 11,045,336 | 0% | held |
| 24 | NRIX Nurix Therapeutics, Inc. | Healthcare | 0.6% | $113.0m | 4,658,556 | 0% | held |
| 25 | STOK Stoke Therapeutics, Inc. | Healthcare | 0.5% | $109.2m | 3,336,697 | 0% | held |
| 26 | GLUE Monte Rosa Therapeutics, Inc. | Healthcare | 0.5% | $105.2m | 4,345,736 | 0% | held |
| 27 | IMTX Immatics N.V. | Healthcare | 0.5% | $96.3m | 9,508,565 | -13% | reduced |
| 28 | DNLI Denali Therapeutics Inc. | Healthcare | 0.5% | $96.0m | 3,734,336 | 0% | held |
| 29 | CRNXGBP Crinetics Pharmaceuticals, Inc. | 0.4% | $88.0m | 2,351,465 | 0% | held | |
| 30 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 0.4% | $83.1m | 852,164 | 0% | held |
| 31 | GPCR Structure Therapeutics Inc. | Healthcare | 0.4% | $76.9m | 1,432,529 | 0% | held |
| 32 | Celcuity Inc. | 0.3% | $69.2m | 30,750,000 | 0% | held | |
| 33 | RAPP Rapport Therapeutics, Inc. | 0.3% | $64.5m | 1,547,090 | 0% | held | |
| 34 | ALMS Alumis Inc. | Healthcare | 0.3% | $56.6m | 2,012,500 | 0% | held |
| 35 | PRLD Prelude Therapeutics Inc. | 0.3% | $54.0m | 10,123,824 | 0% | held | |
| 36 | RLAY Relay Therapeutics, Inc. | Healthcare | 0.3% | $52.9m | 2,826,783 | 144% | added |
| 37 | MIRM Mirum Pharmaceuticals, Inc. | Healthcare | 0.3% | $52.2m | 445,975 | 0% | held |
| 38 | BCYC Bicycle Therapeutics plc | Healthcare | 0.2% | $46.2m | 10,885,357 | 0% | held |
| 39 | ELVN Enliven Therapeutics, Inc. | Healthcare | 0.2% | $45.9m | 905,191 | 0% | held |
| 40 | CLDX Celldex Therapeutics, Inc. | Healthcare | 0.2% | $44.0m | 1,182,611 | 78% | added |
| 41 | VRDN Viridian Therapeutics, Inc. | Healthcare | 0.2% | $43.8m | 2,383,025 | 21% | added |
| 42 | DSGN Design Therapeutics, Inc. | Healthcare | 0.2% | $38.8m | 2,678,430 | 4% | added |
| 43 | TRDA Entrada Therapeutics, Inc. | 0.2% | $37.3m | 5,072,730 | 0% | held | |
| 44 | FTH Faeth Therapeutics, Inc. | 0.2% | $32.2m | 1,286,411 | – | new | |
| 45 | AKTS Aktis Oncology, Inc. | 0.2% | $32.1m | 996,351 | 0% | held | |
| 46 | NGNE Neurogene Inc. | 0.2% | $31.2m | 991,691 | 0% | held | |
| 47 | JBIO Jade Biosciences, Inc. | Healthcare | 0.1% | $27.3m | 1,230,426 | -25% | reduced |
| 48 | TSHA Taysha Gene Therapies, Inc. | Healthcare | 0.1% | $27.3m | 4,004,756 | 0% | held |
| 49 | RCUS Arcus Biosciences, Inc. | Healthcare | 0.1% | $26.0m | 844,816 | 103% | added |
| 50 | IRON Disc Medicine, Inc. | Healthcare | 0.1% | $25.6m | 349,657 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.